MarketBeat
05 Oct 2026, 02:02 UTC · 2h ago
Impact · against what's priced in
Invivyd gains a potential catalyst via an accelerated FDA approval strategy for VYD2311, which could pull forward commercialization to 2027. While safety results are positive, the delay in the placebo-controlled DECLARATION study creates a slight offset to the bullish regulatory outlook.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Invivyd reported that the Phase III LIBERTY study of VYD2311 met its safety and tolerability objectives and showed a statistically significant advantage over an mRNA vaccine.
Newreported topline results
More positive than 93% of claims this week
The company plans to pursue an FDA accelerated-approval pathway for VYD2311 based on serum virus-neutralizing antibody titers.
Continue reading
5 related stories
The plan to pursue accelerated approval based on neutralizing antibody titers potentially accelerates the commercial launch to 2027, though the DECLARATION study results have been delayed by several weeks.
Read from the article alone
No priced-in read yet
VYD2311 demonstrated a lower burden of adverse events and fewer systemic symptoms compared to the COMIRNATY vaccine, suggesting a potentially more tolerable competitive alternative.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
So whatThis strategy seeks to bypass waiting for full clinical-event data, potentially pulling forward the commercial launch date into 2027.
More positive than 86% of claims this week
Results from the placebo-controlled DECLARATION study have been delayed by several weeks from prior guidance.
Newreported topline results
More negative than 78% of claims this week
Invivyd is preparing VYD2311 as a potential replacement for PEMGARDA, whose emergency use authorization winds down next summer.
Priced instanding guidance
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Positive Phase III results for VYD2311 showing safety and tolerability advantages over mRNA vaccines.
More negative than 63% of ticker scores this week
The article notes that Invivyd's candidate showed a lower burden of adverse events and fewer systemic symptoms compared to Pfizer's vaccine.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
—
IVVD hasn't traded since this ran. Last close $0.8221 (Oct 2); the reaction starts at the next open.
IVVD chart →—
PFE hasn't traded since this ran. Last close $27.80 (Oct 2); the reaction starts at the next open.
PFE chart →
